Kinetics of Heterogeneous Background in Stargardt's Disease over Time
- PMID: 35330133
- PMCID: PMC8953836
- DOI: 10.3390/life12030381
Kinetics of Heterogeneous Background in Stargardt's Disease over Time
Abstract
Stargardt's disease (STGD1) is caused by mutations in the ABCA4 gene. Different lesions characterised by decreased autofluorescence levels are found in fundus autofluorescence (FAF) from STGD1 patients and could be used as outcome indicators for disease progression. We investigated the fate of foci with reduced autofluorescence (FRA) within the heterogeneous background of STGD1 patients using FAF imaging. Genetically confirmed STGD1 patients presenting heterogeneous background autofluorescence on high-quality FAF images at a minimum of two visits at least 12 months apart were chosen. A grid centred on the fovea was used to define five different zones. Within each zone, five FRA were randomly selected for each eye. The eccentricity of foci was determined at different time points for each patient. Analysis of 175 randomly chosen FRA showed consistent centrifugal displacement over time, most notably in eyes showing areas with definitely decreased autofluorescence. Interestingly, FRA did not leave an area of hypo-autofluorescence on FAF in locations where they were previously located. These findings may help to better understand STGD1 progression, improve FAF interpretation, and shed light on the nature of heterogeneous background.
Keywords: Stargardt’s disease; definitely decreased autofluorescence; foci with reduced autofluorescence; fundus autofluorescence; heterogeneous background; kinetics.
Conflict of interest statement
The authors declare that they have no conflict of interest. The authors alone are responsible for the content and writing of the paper. E.R.-B. has no financial disclosure. However, M.B. would like to disclosure that he received remuneration from Roche. L.L.F. and M.G. receive remuneration from Novartis and Roche. J.M. receives remuneration from Alcon, Bayer, Genentech, Inc, Iveric Bio, Novartis, Ophthotech, Reneuron and Roche. M.D.F. is on the advisory board of and/or consulting and/or receiving honoraria/grant money/travel support from following companies: Adelphi Values, Advent France Biotechnology, Alphasights, Arctos, Atheneum, Axiom Healthcare Strategies, Biogen, Decision Resources, Dialectica, Frontera Therapeutics, Janssen Research & Development, Navigant, Novartis, Roche, RegenxBio, Sirion, STZeyetrial. M.D.F. is director of Fischer Consulting Limited and holds a patent (50%) on a gene therapy product for X-linked Retinitis Pigmentosa.
Figures
References
-
- Blacharsky P. Retinal Dystrophies and Degenerations. Raven Press; New York, NY, USA: 1988. Fundus flavimaculatus; pp. 132–139.
-
- Allikmets R., Singh N., Sun H., Shroyer N.F., Hutchinson A., Chidambaram A., Gerrard B., Baird L., Stauffer D., Peiffer A., et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat. Genet. 1997;15:236–246. doi: 10.1038/ng0397-236. - DOI - PubMed
-
- Bither P.P., Berns L.A. Stargardt’s disease: A review of the literature. J. Am. Optom. Assoc. 1988;59:106–111. - PubMed
LinkOut - more resources
Full Text Sources
